Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III) | Orphanet Journal of Rare Diseases | Full Text

Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III) | Orphanet Journal of Rare Diseases | Full Text

Orphanet Journal of Rare Diseases

Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III)

• Nicole M. Muschol†,
• Daniel Pape†,
• Kai Kossow,
• Kurt Ullrich,
• Laila Arash-Kaps,
• Julia B. Hennermann,
• Ralf Stücker and
• Sandra R. BreyerEmail authorView ORCID ID profile

†Contributed equally

Orphanet Journal of Rare Diseases201914:93

https://doi.org/10.1186/s13023-019-1065-x

©  The Author(s). 2019

• Received: 14 February 2019
• Accepted: 16 April 2019
• Published: 2 May 2019

Abstract

Background

Mucopolysaccharidosis (MPS) type III (Sanfilippo syndrome) comprises a group of rare, lysosomal storage diseases caused by the deficiency of one of four enzymes involved in the degradation of heparan sulfate. The clinical hallmark of the disease is severe neurological deterioration leading to dementia and death in the second decade of life. Adult MPS patients are generally of short stature. To date there is no clear description of the physical development of MPS III patients. The aim of this study was to document growth reference data for MPS III patients. We collected growth data of 182 German MPS III patients and were able to develop growth charts for this cohort. Growth curves for height, weight, head circumference, and body mass index were calculated and compared to German reference charts.

Results

Birth height, weight and head circumference were within the physiological ranges. Both genders were significantly taller than healthy children at 2 years of age, while only male patients were taller at the age of four. Growth velocity decelerated after the ages of 4.5 and 5 years for female and male patients, respectively. Both genders were significantly shorter than the reference group at the age of 17.5 years. Head circumference was larger compared to healthy matched controls within the first 2 years of life and remained enlarged until physical maturity.

Conclusion

MPS III is a not yet treatable severe neuro-degenerative disease, developing new therapeutic strategies might change the course of the disease significantly. The present charts contribute to the understanding of the natural history of MPS III. Specific growth charts represent an important tool for families and physicians as the expected height at physical maturity can be estimated and therapeutic effects can be monitored.

Keywords

• Mucopolysaccharidosis type III
• Sanfilippo syndrome
• Growth charts
• Weight
• Body height
• Head circumference
• Growth velocity
• Body mass index
• Puberty